|An illustration of goiter, a type of thyroid disease|
|Specialty||Endocrinology, Medical genetics|
Thyroid disease is a medical condition that affects the function of the thyroid gland (the endocrine organ found at the front of the neck that produces thyroid hormones). The symptoms of thyroid disease vary depending on the type. There are four general types: 1) hypothyroidism (low function) caused by not having enough thyroid hormones; 2) hyperthyroidism (high function) caused by having too much thyroid hormones; 3) structural abnormalities, most commonly an enlargement of the thyroid gland; and 4) tumors which can be benign or cancerous. It is also possible to have abnormal thyroid function tests without any clinical symptoms. Common hypothyroid symptoms include fatigue, low energy, weight gain, inability to tolerate the cold, slow heart rate, dry skin and constipation. Common hyperthyroid symptoms include irritability, weight loss, fast heartbeat, heat intolerance, diarrhea, and enlargement of the thyroid. In both hypothyroidism and hyperthyroidism, there may be swelling of a part of the neck, which is also known as goiter.
Diagnosis can often be made through laboratory tests. The first is thyroid-stimulating hormone (TSH), which is generally below normal in hyperthyroidism and above normal in hypothyroidism. The other useful laboratory test is non-protein-bound thyroxine or free T4. Total and free triiodothyronine (T3) levels are less commonly used. Anti-thyroid autoantibodies can also be used, where elevated anti-thyroglobulin and anti-thyroid peroxidase antibodies are commonly found in hypothyroidism from Hashimoto's thyroiditis and TSH-receptor antibodies are found in hyperthyroidism caused by Graves' disease. Procedures such as ultrasound, biopsy and a radioiodine scanning and uptake study may also be used to help with the diagnosis.
Treatment of thyroid disease varies based on the disorder. Levothyroxine is the mainstay of treatment for people with hypothyroidism, while people with hyperthyroidism caused by Graves' disease can be managed with iodine therapy, antithyroid medication, or surgical removal of the thyroid gland. Thyroid surgery may also be performed to remove a thyroid nodule or lobe for biopsy, or if there is a goiter that is unsightly or obstructs nearby structures.
Hypothyroidism affects 3-10% percent of adults, with a higher incidence in women and the elderly. An estimated one-third of the world's population currently lives in areas of low dietary iodine levels, making iodine-deficiency the most common cause of hypothyroidism and endemic goiter. In regions of severe iodine deficiency, the prevalence of goiter is as high as 80%. In areas where iodine-deficiency is not found, the most common type of hypothyroidism is an autoimmune subtype called Hashimoto's thyroiditis, with a prevalence of 1-2%. As for hyperthyroidism, Graves' disease, another autoimmune condition, is the most common type with a prevalence of 0.5% in males and 3% in females. Although thyroid nodules are common, thyroid cancer is rare. Thyroid cancer accounts for less than 1% of all cancer in the UK, though it is the most common endocrine tumor and makes up greater than 90% of all cancers of the endocrine glands.
- 1 Signs and symptoms
- 2 Diseases
- 3 Diagnosis
- 4 Treatment
- 5 References
- 6 External links
Signs and symptoms
Symptoms of the condition vary with type: hypo- vs. hyperthyroidism, which are further described below.
Note: certain symptoms and physical changes can be seen in both hypothyroidism and hyperthyroidism —fatigue, fine / thinning hair, menstrual cycle irregularities, muscle weakness / aches (myalgia), and different forms of myxedema.
Hypothyroidism is a state in which the body is not producing enough thyroid hormones, or is not able to respond to / utilize existing thyroid hormones properly. The main categories are:
- Thyroiditis: an inflammation of the thyroid gland
- Iatrogenic hypothyroidism
- Postoperative hypothyroidism
- Medication- or radiation-induced hypothyroidism
- Thyroid hormone resistance
- Euthyroid sick syndrome
- Congenital hypothyroidism: a deficiency of thyroid hormone from birth, which untreated can lead to cretinism
Hyperthyroidism is a state in which the body is producing too much thyroid hormone. The main hyperthyroid conditions are:
- Graves' disease
- Toxic thyroid nodule
- Thyroid storm
- Toxic nodular struma (Plummer's disease)
- Hashitoxicosis: transient hyperthyroidism that can occur in Hashimoto's thyroiditis
- Goiter: an abnormal enlargement of the thyroid gland
- Lingual thyroid
- Thyroglossal duct cyst
- Thyroid adenoma: benign / non-cancerous tumor
- Thyroid cancer
- Lymphomas and metastasis from elsewhere (rare)
Medication side effects
Certain medications can have the unintended side effect of affecting thyroid function. While some medications can lead to significant hypothyroidism or hyperthyroidism and those at risk will need to be carefully monitored, some medications may affect thyroid hormone lab tests without causing any symptoms or clinical changes, and may not require treatment. The following medications have been linked to various forms of thyroid disease:
- Amiodarone (more commonly can lead to hypothyroidism, but can be associated with some types of hyperthyroidism)
- Lithium salts (hypothyroidism)
- Some types of interferon and IL-2 (thyroiditis)
- Glucocorticoids, dopamine agonists, and somatostatin analogs (block TSH, which can lead to hypothyroidism)
Diagnosis of thyroid disease depends on symptoms and whether or not a thyroid nodule is present. Most patients will receive a blood test. Others might need an ultrasound, biopsy or a radioiodine scanning and uptake study.
Thyroid function tests
There are several hormones that can be measured in the blood to determine how the thyroid gland is functioning. These include the thyroid hormones triiodothyronine (T3) and its precursor thyroxine (T4), which are produced by the thyroid gland. Thyroid-stimulating hormone (TSH) is another important hormone that is secreted by the anterior pituitary cells in the brain. Its primary function is to increase the production of T3 and T4 by the thyroid gland.
The most useful marker of thyroid gland function is serum thyroid-stimulating hormone (TSH) levels. TSH levels are determined by a classic negative feedback system in which high levels of T3 and T4 suppress the production of TSH, and low levels of T3 and T4 increase the production of TSH. TSH levels are thus often used by doctors as a screening test, where the first approach is to determine whether TSH is elevated, suppressed, or normal.
- Elevated TSH levels can signify inadequate thyroid hormone production (hypothyroidism)
- Suppressed TSH levels can point to excessive thyroid hormone production (hyperthyroidism)
Because a single abnormal TSH level can be misleading, T3 and T4 levels must be measured in the blood to further confirm the diagnosis. When circulating in the body, T3 and T4 are bound to transport proteins. Only a small fraction of the circulating thyroid hormones are unbound or free, and thus biologically active. T3 and T4 levels can thus be measured as free T3 and T4, or total T3 and T4, which takes into consideration the free hormones in addition to the protein-bound hormones. Free T3 and T4 measurements are important because certain drugs and illnesses can affect the concentrations of transport proteins, resulting in differing total and free thyroid hormone levels. There are differing guidelines for T3 and T4 measurements.
- Free T4 levels should be measured in the evaluation of hypothyroidism, and low free T4 establishes the diagnosis. T3 levels are generally not measured in the evaluation of hypothyroidism.
- Free T4 and total T3 can be measured when hyperthyroidism is of high suspicion as it will improve the accuracy of the diagnosis. Free T4, total T3 or both are elevated and serum TSH is below normal in hyperthyroidism. If the hyperthyroidism is mild, only serum T3 may be elevated and serum TSH can be low or may not be detected in the blood.
- Free T4 levels may also be tested in patients who have convincing symptoms of hyper- and hypothyroidism, despite a normal TSH.
Autoantibodies to the thyroid gland may be detected in various disease states. There are several anti-thyroid antibodies, including anti-thyroglobulin antibodies (TgAb), anti-microsomal/anti-thyroid peroxidase antibodies (TPOAb), and TSH receptor antibodies (TSHRAb).
- Elevated anti-thryoglobulin (TgAb) and anti-thyroid peroxidase antibodies (TPOAb) can be found in patients with Hashimoto's thyroiditis, the most common autoimmune type of hypothyroidism. TPOAb levels have also been found to be elevated in patients who present with subclinical hypothyroidism (where TSH is elevated, but free T4 is normal), and can help predict progression to overt hypothyroidism. The American Association Thyroid Association thus recommends measuring TPOAb levels when evaluating subclinical hypothyroidism or when trying to identify whether nodular thyroid disease is due to autoimmune thyroid disease.
- When the etiology of hyperthyroidism is not clear after initial clinical and biochemical evaluation, measurement of TSH receptor antibodies (TSHRAb) can help make the diagnosis. In Grave's disease, TSHRAb levels are elevated as they are responsible for activating the TSH receptor and causing increased thyroid hormone production.
- There are two markers for thyroid-derived cancers.
- Thyroglobulin (TG) levels can be elevated in well-differentiated papillary or follicular adenocarcinoma. It is often used to provide information on residual, recurrent or metastatic disease in patients with differentiated thyroid cancer. However, serum TG levels can be elevated in most thyroid diseases. Routine measurement of serum TG for evaluation of thyroid nodules is thus currently not recommended by the American Thyroid Association.
- Elevated calcitonin levels in the blood have been shown to be associated with the rare medullary thyroid cancer. However, the measurement of calcitonin levels as a diagnostic tool is currently controversial due to falsely high or low calcitonin levels in a variety of diseases other than medullary thyroid cancer.
- Very infrequently, TBG and transthyretin levels may be abnormal; these are not routinely tested.
- To differentiate between different types of hypothyroidism, a specific test may be used. Thyrotropin-releasing hormone (TRH) is injected into the body through a vein. This hormone is naturally secreted by the hypothalamus and stimulates the pituitary gland. The pituitary responds by releasing thyroid-stimulating hormone (TSH). Large amounts of externally administered TRH can suppress the subsequent release of TSH. This amount of release-suppression is exaggerated in primary hypothyroidism, major depression, cocaine dependence, amphetamine dependence and chronic phencyclidine abuse. There is a failure to suppress in the manic phase of bipolar disorder.
Many people may develop a thyroid nodule at some point in their lives. Although many who experience this worry that it is thyroid cancer, there are many causes of nodules that are benign and not cancerous. If a possible nodule is present, a doctor may order thyroid function tests to determine if the thyroid gland's activity is being affected. If more information is needed after a clinical exam and lab tests, medical ultrasonography can help determine the nature of thyroid nodule(s). There are some notable differences in typical benign vs. cancerous thyroid nodules that can particularly be detected by the high-frequency sound waves in an ultrasound scan. The ultrasound may also locate nodules that are too small for a doctor to feel on a physical exam, and can demonstrate whether a nodule is primarily solid, liquid (cystic), or a mixture of both. It is an imaging process that can often be done in a doctor's office, is painless, and does not expose the individual to any radiation.
The main characteristics that can help distinguish a benign vs. malignant (cancerous) thyroid nodule on ultrasound are as follows:
|Possible thyroid cancer||More likely benign|
|irregular borders||smooth borders|
|hypoechoic (less echogenic than the surrounding tissue)||hyperechoic|
|incomplete "halo"||spongiform appearance|
|significant intranodular / central blood flow by power Doppler||marked peripheral blood flow|
|microcalcifications||larger, broad calcifications (note: these can be seen in medullary thyroid cancer)|
|nodule appears more tall than wide on transverse study||"comet tail" artifact as sound waves bounce off intranodular colloid|
|documented progressive increase in size of nodule on ultrasound|
Although ultrasonography is a very important diagnostic tool, this method is not always able to separate benign from malignant nodules with certainty. In suspicious cases, a tissue sample is often obtained by biopsy for microscopic examination.
Radioiodine scanning and uptake
Thyroid scintigraphy, in which the thyroid is imaged with the aid of radioactive iodine (usually iodine-123, which does not harm thyroid cells, or rarely, iodine-131), is performed in the nuclear medicine department of a hospital or clinic. Radioiodine collects in the thyroid gland before being excreted in the urine. While in the thyroid, the radioactive emissions can be detected by a camera, producing a rough image of the shape (a radioiodine scan) and tissue activity (a radioiodine uptake) of the thyroid gland.
A normal radioiodine scan shows even uptake and activity throughout the gland. Irregular uptake can reflect an abnormally shaped or abnormally located gland, or it can indicate that a portion of the gland is overactive or underactive. For example, a nodule that is overactive ("hot") -- to the point of suppressing the activity of the rest of the gland—is usually a thyrotoxic adenoma, a surgically curable form of hyperthyroidism that is rarely malignant. In contrast, finding that a substantial section of the thyroid is inactive ("cold") may indicate an area of non-functioning tissue, such as thyroid cancer.
The amount of radioactivity can be quantified and serves as an indicator of the metabolic activity of the gland. A normal quantitation of radioiodine uptake demonstrates that about 8-35% of the administered dose can be detected in the thyroid 24 hours later. Overactivity or underactivity of the gland, as may occur with hyperthyroidism or hypothyroidism, is usually reflected in increased or decreased radioiodine uptake. Different patterns may occur with different causes of hypo- or hyperthyroidism.
A medical biopsy refers to the obtaining of a tissue sample for examination under the microscope or other testing, usually to distinguish cancer from noncancerous conditions. Thyroid tissue may be obtained for biopsy by fine needle aspiration (FNA) or by surgery.
Fine needle aspiration has the advantage of being a brief, safe, outpatient procedure that is safer and less expensive than surgery and does not leave a visible scar. Needle biopsies became widely used in the 1980s, but it was recognized that the accuracy of identification of cancer was good, but not perfect. The accuracy of the diagnosis depends on obtaining tissue from all of the suspicious areas of an abnormal thyroid gland. The reliability of fine needle aspiration is increased when sampling can be guided by ultrasound, and over the last 15 years, this has become the preferred method for thyroid biopsy in North America.
Levothyroxine is a stereoisomer of thyroxine (T4) which is degraded much more slowly and can be administered once daily in patients with hypothyroidism. Natural thyroid hormone from pigs is sometimes also used, especially for people who cannot tolerate the synthetic version. Hyperthyroidism caused by Graves' disease may be treated with the thioamide drugs propylthiouracil, carbimazole or methimazole, or rarely with Lugol's solution. Additionally, hyperthyroidism and thyroid tumors may be treated with radioactive iodine. Ethanol injections for the treatment of recurrent thyroid cysts and metastatic thyroid cancer in lymph nodes can also be an alternative to surgery.
Thyroid surgery is performed for a variety of reasons. A nodule or lobe of the thyroid is sometimes removed for biopsy or because of the presence of an autonomously functioning adenoma causing hyperthyroidism. A large majority of the thyroid may be removed (subtotal thyroidectomy) to treat the hyperthyroidism of Graves' disease, or to remove a goiter that is unsightly or impinges on vital structures.
A complete thyroidectomy of the entire thyroid, including associated lymph nodes, is the preferred treatment for thyroid cancer. Removal of the bulk of the thyroid gland usually produces hypothyroidism unless the person takes thyroid hormone replacement. Consequently, individuals who have undergone a total thyroidectomy are typically placed on thyroid hormone replacement (e.g. Levothyroxine) for the remainder of their lives. Higher than normal doses are often administered to prevent recurrence.
If the thyroid gland must be removed surgically, care must be taken to avoid damage to adjacent structures, the parathyroid glands and the recurrent laryngeal nerve. Both are susceptible to accidental removal and/or injury during thyroid surgery.
The parathyroid glands produce parathyroid hormone (PTH), a hormone needed to maintain adequate amounts of calcium in the blood. Removal results in hypoparathyroidism and a need for supplemental calcium and vitamin D each day. In the event that the blood supply to any one of the parathyroid glands is endangered through surgery, the parathyroid gland(s) involved may be re-implanted in surrounding muscle tissue.
The recurrent laryngeal nerves provide motor control for all external muscles of the larynx except for the cricothyroid muscle, which also runs along the posterior thyroid. Accidental laceration of either of the two or both recurrent laryngeal nerves may cause paralysis of the vocal cords and their associated muscles, changing the voice quality.
Radioiodine therapy with iodine-131 can be used to shrink the thyroid gland (for instance, in the case of large goiters that cause symptoms but do not harbor cancer—after evaluation and biopsy of suspicious nodules has been done), or to destroy hyperactive thyroid cells (for example, in cases of thyroid cancer). The iodine uptake can be high in countries with iodine deficiency, but low in iodine sufficient countries. To enhance iodine-131 uptake by the thyroid and allow for more successful treatment, TSH is raised prior to therapy in order to stimulate the existing thyroid cells. This is done either by withdrawal of thyroid hormone medication or injections of recombinant human TSH (Thyrogen), released in the United States in 1999. Thyrogen injections can reportedly boost uptake up to 50-60%. Radioiodine treatment can also cause hypothyroidism (which is sometimes the end goal of treatment) and, although rare, a pain syndrome (due to radiation thyroiditis).
- C., Guyton, Arthur. Guyton and Hall textbook of medical physiology. OCLC 434319356.
- Bauer, DC; et al. (2013). Pathophysiology of Disease: An Introduction to Clinical Medicine, Seventh Edition. New York, NY.: McGraw-Hill – via AccessMedicine.
- "Hypothyroidism (Underactive Thyroid)". www.niddk.nih.gov. Retrieved 2016-12-16.
- "Hyperthyroidism". www.niddk.nih.gov. Retrieved 2016-12-16.
- Garber, Jeffrey; Cobin, Rhoda; Gharib, Hossein; Hennessey, James; Klein, Irwin; Mechanick, Jeffrey; Pessah-Pollack, Rachel; Singer, Peter; Woeber, Kenneth (2012-12-17). "Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association". Endocrine Practice. 18 (6): 988–1028. doi:10.4158/ep12280.gl. PMID 23246686.
- Ross, Douglas S.; Burch, Henry B.; Cooper, David S.; Greenlee, M. Carol; Laurberg, Peter; Maia, Ana Luiza; Rivkees, Scott A.; Samuels, Mary; Sosa, Julie Ann (2016-08-12). "2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis" (PDF). Thyroid (Submitted manuscript). 26 (10): 1343–1421. doi:10.1089/thy.2016.0229. ISSN 1050-7256. PMID 27521067.
- Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT (2004). "Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society". Endocr Pract. 10 (6): 497–501. doi:10.4158/ep.10.6.497. PMID 16033723.
- Fatourechi V (2009). "Subclinical hypothyroidism: an update for primary care physicians". Mayo Clin. Proc. 84 (1): 65–71. doi:10.4065/84.1.65. PMC 2664572. PMID 19121255.
- Villar HC, Saconato H, Valente O, Atallah AN (2007). Villar HC, ed. "Thyroid hormone replacement for subclinical hypothyroidism". Cochrane Database Syst Rev (3): CD003419. doi:10.1002/14651858.CD003419.pub2. PMID 17636722.
- Vanderpump, M. P. J. (2011-09-01). "The epidemiology of thyroid disease". British Medical Bulletin. 99 (1): 39–51. doi:10.1093/bmb/ldr030. ISSN 0007-1420. PMID 21893493.
- Burch, Henry B.; Cooper, David S. (2015-12-15). "Management of Graves Disease". JAMA. 314 (23): 2544–54. doi:10.1001/jama.2015.16535. ISSN 0098-7484. PMID 26670972.
- "Hypothyroidism - American Thyroid Association". www.thyroid.org. Retrieved 2017-04-25.
- Choices, NHS. "Underactive thyroid (hypothyroidism) - Symptoms - NHS Choices". www.nhs.uk. Retrieved 17 December 2016.
- "Hyperthyroidism - American Thyroid Association". www.thyroid.org. Retrieved 2017-04-25.
- "Hyperthyroidism - American Thyroid Association". www.thyroid.org. Retrieved 2016-12-13.
- "Hypothyroidism - American Thyroid Association". www.thyroid.org. Retrieved 2016-12-13.
- Vitti, Paolo; Latrofa, Francesco (2013-01-01). Surgery, Paolo Miccoli MDessor of; Chairman, David J. Terris MD, FACS Surgical Director, Georgia Health Thyroid/Parathyroid Center, Porubskyessor and; Surgery, Michele N. Minuto MD, Assistantessor of; Seybt, Melanie W., eds. Thyroid Surgery. John Wiley & Sons, Ltd. pp. 291–303. doi:10.1002/9781118444832.ch32/summary (inactive 2018-11-03). ISBN 9781118444832.
- Batcher, Elizabeth L.; Tang, X. Charlene; Singh, Bramah N.; Singh, Steven N.; Reda, Domenic J.; Hershman, Jerome M. (October 2007). "Thyroid Function Abnormalities during Amiodarone Therapy for Persistent Atrial Fibrillation". The American Journal of Medicine. 120 (10): 880–885. doi:10.1016/j.amjmed.2007.04.022. PMID 17904459.
- Haugen, Bryan R. (2016-12-13). "Drugs that suppress TSH or cause central hypothyroidism". Best Practice & Research. Clinical Endocrinology & Metabolism. 23 (6): 793–800. doi:10.1016/j.beem.2009.08.003. ISSN 1521-690X. PMC 2784889. PMID 19942154.
- Jameson, J; et al. (2015). Harrison's Principal of Internal Medicine, 19e. New York: NY: McGraw-Hill. pp. Ch 405 – via Access Medicine.
- Haugen, Bryan R.; Alexander, Erik K.; Bible, Keith C.; Doherty, Gerard M.; Mandel, Susan J.; Nikiforov, Yuri E.; Pacini, Furio; Randolph, Gregory W.; Sawka, Anna M. (2015-10-14). "2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer". Thyroid. 26 (1): 1–133. doi:10.1089/thy.2015.0020. ISSN 1050-7256. PMC 4739132. PMID 26462967.
- Wells, Samuel A.; Asa, Sylvia L.; Dralle, Henning; Elisei, Rossella; Evans, Douglas B.; Gagel, Robert F.; Lee, Nancy; Machens, Andreas; Moley, Jeffrey F. (2015-03-26). "Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma". Thyroid. 25 (6): 567–610. doi:10.1089/thy.2014.0335. ISSN 1050-7256. PMC 4490627. PMID 25810047.
- Giannini AJ, Malone DA, Loiselle RH, Price WA (1987). "Blunting of TSH response to TRH in chronic cocaine and phencyclidine abusers". J Clin Psychiatry. 48 (1): 25–6. PMID 3100509.
- "Thyroid Nodules - American Thyroid Association". www.thyroid.org. Retrieved 2016-12-13.
- "Diagnostic approach to and treatment of thyroid nodules". www.uptodate.com. Retrieved 2016-12-13.
- "Radioactive Iodine - American Thyroid Association". www.thyroid.org. Retrieved 2016-12-14.
- Kinjal K Shah; Valentina D. Tarasova; Michael Davidian; Robert J Anderson (2014-06-01). "Non-Neoplastic Thyroid Disorders-Clinical and Case Reports". Endo Meetings. Meeting Abstracts: SAT–0523–SAT–0523. doi:10.1210/endo-meetings.2014.thpta.3.sat-0523 (inactive 2018-11-03).